.INVESTIGATION FEATURE.06 August 2024.
A sizable randomized controlled trial with cisgender women highlights the challenges of adherence to a regular oral preexposure prophylaxis regiment and displays that twice-yearly treatment of lenacapavir may keep efficient HIV protection degrees over 6 months.